Payment overview · 2025
General Payments
$2,057.85
145 reported records · 18 companies
Healthcare provider profile · identity verified
Brian Garland, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT SMITH, AR · NPI 1811551039
Verified facts
What the public records show
CMS Open Payments records show Brian Garland, MD received $2,057.85 in general payments during 2025 across 145 reported records.
ABBVIE INC. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $472.80 | 23.0% | 43 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $359.95 | 17.5% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $258.03 | 12.5% | 31 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $232.23 | 11.3% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $198.50 | 9.7% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $106.77 | 5.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $96.53 | 4.7% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $91.78 | 4.5% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.32 | 2.1% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $44.29 | 2.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.08 | 1.5% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $27.80 | 1.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.75 | 1.1% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $19.43 | 0.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.27 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.61 | 0.8% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $13.92 | 0.7% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $6.79 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,057.85 | 145 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $258.64 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $243.41 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $234.75 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $226.37 | 28 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $220.34 | 26 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $214.16 | 27 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $198.50 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $168.72 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $128.52 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.33 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $118.21 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $103.16 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $91.78 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $81.43 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $81.43 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.21 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.32 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $44.29 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.66 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.66 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.66 | 3 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $27.80 | 2 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $6.79 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $6.03 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 64 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 342 | 103 |
| Gabapentin | Gabapentin | 288 | 76 |
| Lisinopril | Lisinopril | 284 | 83 |
| Omeprazole | Omeprazole | 265 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 226 | 52 |
| Meloxicam | Meloxicam | 211 | 59 |
| Furosemide | Furosemide | 209 | 56 |
| Trazodone Hcl | Trazodone Hcl | 162 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 161 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 53 |
| Tramadol Hcl | Tramadol Hcl | 157 | 59 |
| Alprazolam | Alprazolam | 156 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 40 |
| Metformin Hcl | Metformin Hcl | 148 | 54 |
| Prednisone | Prednisone | 145 | 88 |
| Losartan Potassium | Losartan Potassium | 143 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 37 |
| Ozempic | Semaglutide | 138 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 32 |
| Potassium Chloride | Potassium Chloride | 124 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 36 |
| Montelukast Sodium | Montelukast Sodium | 115 | 31 |
| Buspirone Hcl | Buspirone Hcl | 113 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 37 |
| Pregabalin | Pregabalin | 109 | 26 |
| Mirtazapine | Mirtazapine | 108 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 37 |
| Jardiance | Empagliflozin | 99 | 26 |
| Alendronate Sodium | Alendronate Sodium | 98 | 28 |
| Clonazepam | Clonazepam | 94 | 21 |
| Simvastatin | Simvastatin | 94 | 25 |
| Sertraline Hcl | Sertraline Hcl | 88 | 25 |
| Carvedilol | Carvedilol | 86 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 72 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 21 |
| Eliquis | Apixaban | 64 | 18 |
| Farxiga | Dapagliflozin Propanediol | 63 | suppressed |
| Spironolactone | Spironolactone | 61 | 14 |
| Glipizide Er | Glipizide | 60 | 22 |
| Methylprednisolone | Methylprednisolone | 59 | 53 |
| Baclofen | Baclofen | 58 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 12 |
| Allopurinol | Allopurinol | 48 | 15 |
| Atenolol | Atenolol | 48 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 36 |
| Lorazepam | Lorazepam | 47 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 12 |
| Clonidine Hcl | Clonidine Hcl | 45 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 18 |
| Glipizide | Glipizide | 43 | 16 |
| Temazepam | Temazepam | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 12 |
| Celecoxib | Celecoxib | 40 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 40 | 12 |
| Famotidine | Famotidine | 39 | 11 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 36 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 13 |
| Sucralfate | Sucralfate | 34 | 20 |
| Diazepam | Diazepam | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Azithromycin | Azithromycin | 29 | 27 |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 13 |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 11 |
| Estradiol | Estradiol | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 18 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | 12 |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,057.85 · 145 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Azstarys, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, GEMTESA, Heplisav-B, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, QUTENZA, REPATHA, REXULTI, Rybelsus, TZIELD, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error